AbbVie Inc (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2016.
“AbbVie delivered strong first-quarter results, including significant revenue and EPS growth, and margin expansion,” saidRichard A. Gonzalez, chairman and chief executive officer, AbbVie. “In addition to our strong financial performance, we also continue to advance several strategic priorities, including the addition of two highly compelling late-stage pipeline assets through the Stemcentrx acquisition and BI collaboration. We also secured two important approvals with the expansion of the IMBRUVICA label into first-line CLL and the recent approval of Venclexta. We expect 2016 to be a year of top-tier financial performance for AbbVie and we’re off to an exceptional start.”
- Worldwide net revenues were $5.96 billion in the first quarter, up 18.2 percent. On an operational basis, net revenues increased 22.4 percent, excluding a 4.2 percent unfavorable impact from foreign exchange rate fluctuations.
- Global HUMIRA sales increased 19.2 percent on an operational basis, excluding the impact of foreign exchange. Reported HUMIRA sales increased 14.9 percent. Strong U.S. HUMIRA growth was driven by continued momentum across all three major market categories – rheumatology, dermatology and gastroenterology. International HUMIRA sales growth was also strong in the first quarter and ahead of our guidance.
- First quarter global IMBRUVICA net revenue was $381 million, with U.S. sales of $325 million and international profit sharing of $56 million for the quarter.
- Total company revenue growth was also driven by $414 million in global VIEKIRA sales in the quarter, as well as strong operational growth from Duodopa and Creon.
- Adjusted gross margin ratio in the first quarter was 81.3 percent, excluding intangible asset amortization and other specified items. On a GAAP basis, the gross margin ratio was 77.0 percent.
- Adjusted selling, general and administrative (SG&A) expense was 22.6 percent of net revenues in the first quarter. On a GAAP basis, SG&A was 22.7 percent of net revenues.
- Adjusted research and development (R&D) expense was 15.6 percent of net revenues in the quarter, reflecting funding actions supporting all stages of our pipeline. On a GAAP basis, R&D was 15.9 percent.
- Adjusted operating margin in the first quarter was 43.1 percent, compared to 40.1 percent in first-quarter 2015. On a GAAP basis, the operating margin was 38.2 percent.
- Net interest expense was $200 million. The adjusted tax rate in the quarter was 20.7 percent and 23.7 percent on a GAAP basis.
- Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were$1.15 in the first quarter, up 22.3 percent. Diluted earnings per share were $0.83 on a GAAP basis, including a $298 million foreign exchange loss related to a devaluation of AbbVie’s net monetary assets denominated in the Venezuelan bolivar.
Key Events from the First Quarter
- The U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) as a first-line therapy for the treatment of chronic lymphocytic leukemia (CLL). This approval was based on data from the Phase 3 RESONATE™-2 trial, which found that treatment with IMBRUVICA significantly decreased the risk of progression or death (progression-free survival, PFS) versus chlorambucil. Following the approval, the National Comprehensive Cancer Network (NCCN) updated its treatment guidelines, granting IMBRUVICA a category 1 recommendation for certain CLL patients, which is the highest recommendation assigned by the organization. The NCCN treatment guidelines influence prescribing and reimbursement practices in many institutions in the U.S. and internationally. IMBRUVICA is also currently under regulatory review by the European Medicines Agency (EMA) as a first-line therapy option for CLL patients.
- On April 11, AbbVie received accelerated FDA approval of Venclexta™ (venetoclax) for patients with relapsed/refractory (R/R) CLL with chromosome 17p deletion, a condition which is typically associated with a poor prognosis, and found in up to 30 to 50 percent of these previously-treated patients. The approval is based on results from a Phase 2, open-label trial, which found that treatment with Venclexta demonstrated an 80 percent overall response rate (ORR) as monotherapy treatment, including patients that achieved complete remission. This indication is currently under review by the EMA, which validated AbbVie’s Marketing Authorization Application earlier this year. TheFDA also previously granted Breakthrough Therapy designations for venetoclax combination therapy with rituximab for patients with R/R CLL and in combination with hypomethylating agents (HMAs) in patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy).
- AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize risankizumab (BI 655066), an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn’s disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gained rights to an anti-CD-40 antibody, BI 655064, currently in Phase 1 development.
- AbbVie presented new data from its investigational chronic hepatitis C virus (HCV) infection development program for ABT-493 and ABT-530, a once-daily, ribavirin (RBV)-free, pan-genotypic regimen at The International Liver Congress™ (EASL). Results from the SURVEYOR-1 and 2 studies found that with eight weeks of treatment, 97-98 percent of genotype 1-3 (GT1-3) HCV infected patients without cirrhosis treated with the regimen achieved sustained virologic response at 12 weeks post-treatment (SVR12). Additionally, 100 percent of genotype 4-6 (GT4-6) patients without cirrhosis achieved SVR12 with 12 weeks of treatment. SURVEYOR-2 further demonstrated that GT3 patients with compensated cirrhosis (Child-Pugh A), historically considered difficult-to-treat, achieved 100 percent SVR12 with 12 weeks of treatment. Additionally, results from the MAGELLAN-1 study demonstrated that SVR12 was achieved in 95 percent of patients with and without RBV in a modified intent-to-treat analysis, excluding patients who did not achieve SVR for reasons other than virologic failure. Further results from AbbVie’s investigational HCV development program will be presented later in the year and the company anticipates commercialization of the next-generation combination in 2017.
- AbbVie and Neurocrine Biosciences, Inc. announced positive top-line results from the second of two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of elagolix in premenopausal women who suffer pain from endometriosis. Study results demonstrated that after six months of continuous treatment, both doses of elagolix (150 mg once daily and 200 mg twice daily) met the study’s co-primary endpoints. Elagolix reduced scores of menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis, at month three and month six, as measured by the Daily Assessment of Endometriosis Pain scale. Responder rates for the co-primary endpoints from this second Phase 3 pivotal study are consistent with results from the first Phase 3 pivotal study. The companies also announced the initiation of Phase 3 trials of elagolix for the management of uterine fibroids in the quarter.
- AbbVie announced that it received CHMP positive opinion for HUMIRA® (adalimumab) for the treatment of pediatric patients aged six years or older, with moderate to severe active Crohn’s disease. HUMIRA is currently approved in theEuropean Union (EU) for pediatric patients with severe active Crohn’s disease. If the variation to the current marketing authorization for HUMIRA in these patients is approved, it will validate the expanded label in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway.
Full-Year 2016 Outlook
AbbVie is updating its diluted earnings-per-share guidance to include the impact of the Stemcentrx acquisition, which is expected to be $0.20 dilutive in 2016. As a result, AbbVie now expects diluted earnings-per-share of $4.62 to $4.82 on an adjusted basis for the full-year 2016, representing 10 percent growth versus 2015 at the midpoint. The company’s 2016 adjusted diluted earnings-per-share guidance excludes $0.75 per share of intangible asset amortization expense, the impact of the Venezuelan currency devaluation, and other specified items. Including these items, AbbVie’s diluted earnings-per-share guidance is $3.87 to $4.07 on a GAAP basis. (Original Source)
Shares of AbbVie are down over 2% in pre-market trading. ABBV has a 1-year high of $71.60 and a 1-year low of $45.45. The stock’s 50-day moving average is $57.90 and its 200-day moving average is $56.38.
On the ratings front, AbbVie has been the subject of a number of recent research reports. In a report issued on April 7, Societe Generale analyst Justin Smith initiated coverage with a Sell rating on ABBV and a price target of $47, which represents a potential downside of 22.6% from where the stock is currently trading. Separately, on March 15, Deutsche Bank’s Gregg Gilbert initiated coverage with a Hold rating on the stock and has a price target of $63.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Justin Smith and Gregg Gilbert have a total average return of -3.0% and -2.2% respectively. Smith has a success rate of 33.3% and is ranked #2659 out of 3839 analysts, while Gilbert has a success rate of 43.3% and is ranked #3148.
The street is mostly Bullish on ABBV stock. Out of 6 analysts who cover the stock, 4 suggest a Buy rating , one suggests a Sell and one recommends to Hold the stock. The 12-month average price target assigned to the stock is $74.67, which implies an upside of 23.0% from current levels.
AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company’s focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on April 10, 2012 and is headquartered in North Chicago, IL.